Cargando…
The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
INTRODUCTION: There have been no studies directly comparing the effect of dipeptidyl peptidase-4 inhibitors with that of metformin on treatment-related quality of life (QOL) when used as first-line therapy in patients with type 2 diabetes mellitus (T2DM). METHODS: This study is a prospective, random...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349297/ https://www.ncbi.nlm.nih.gov/pubmed/30483953 http://dx.doi.org/10.1007/s13300-018-0539-5 |
_version_ | 1783390249566601216 |
---|---|
author | Mita, Tomoya Hiyoshi, Toru Yoshii, Hidenori Chimori, Hiroko Ikeda, Kazuo Shimizu, Miho Kojima, Yuichi Yamamto, Hareaki Yasuda, Daijiro Sato, Junko Watada, Hirotaka |
author_facet | Mita, Tomoya Hiyoshi, Toru Yoshii, Hidenori Chimori, Hiroko Ikeda, Kazuo Shimizu, Miho Kojima, Yuichi Yamamto, Hareaki Yasuda, Daijiro Sato, Junko Watada, Hirotaka |
author_sort | Mita, Tomoya |
collection | PubMed |
description | INTRODUCTION: There have been no studies directly comparing the effect of dipeptidyl peptidase-4 inhibitors with that of metformin on treatment-related quality of life (QOL) when used as first-line therapy in patients with type 2 diabetes mellitus (T2DM). METHODS: This study is a prospective, randomized, open-label, multicenter, parallel-group, comparative study. Forty-four participants who failed to achieve target glycemic control with diet and exercise therapy were randomly allocated to receive linagliptin or metformin therapy. We compared treatment-related QOL among the two groups using the Oral Hypoglycemic Agent Questionnaire, version 2 (OHA-Q version 2) and the self-administered Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. RESULTS: After randomization, 21 patients in the linagliptin group and 22 patients in the metformin treatment group were included in the full analysis set. Biochemical parameters, incidence of adverse effects, and rate of adherence to medication were comparable between the two groups. Over the 24-week treatment period, no significant differences in overall OHA-Q scores between the groups were observed, although the subscale 1 (treatment convenience) score was significantly higher in the linagliptin group than in the metformin group. The overall DTR-QOL score did not differ between the two groups; however, the DTR-QOL scores significantly improved after 24 weeks of linagliptin treatment, but not after metformin treatment. CONCLUSION: We did not find significantly better treatment-related QOL with linagliptin among Japanese patients with T2DM. In terms of treatment convenience, our data showed that linagliptin was superior to metformin. FUNDING: This study was financially supported by Nippon Boehringer Ingelheim Co., Ltd. and Eli Lilly and Company. The journal’s article processing fees were covered by a research fund from Juntendo University. CLINICAL TRIAL REGISTRATION: UMIN000022953. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0539-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6349297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-63492972019-02-15 The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Mita, Tomoya Hiyoshi, Toru Yoshii, Hidenori Chimori, Hiroko Ikeda, Kazuo Shimizu, Miho Kojima, Yuichi Yamamto, Hareaki Yasuda, Daijiro Sato, Junko Watada, Hirotaka Diabetes Ther Original Research INTRODUCTION: There have been no studies directly comparing the effect of dipeptidyl peptidase-4 inhibitors with that of metformin on treatment-related quality of life (QOL) when used as first-line therapy in patients with type 2 diabetes mellitus (T2DM). METHODS: This study is a prospective, randomized, open-label, multicenter, parallel-group, comparative study. Forty-four participants who failed to achieve target glycemic control with diet and exercise therapy were randomly allocated to receive linagliptin or metformin therapy. We compared treatment-related QOL among the two groups using the Oral Hypoglycemic Agent Questionnaire, version 2 (OHA-Q version 2) and the self-administered Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. RESULTS: After randomization, 21 patients in the linagliptin group and 22 patients in the metformin treatment group were included in the full analysis set. Biochemical parameters, incidence of adverse effects, and rate of adherence to medication were comparable between the two groups. Over the 24-week treatment period, no significant differences in overall OHA-Q scores between the groups were observed, although the subscale 1 (treatment convenience) score was significantly higher in the linagliptin group than in the metformin group. The overall DTR-QOL score did not differ between the two groups; however, the DTR-QOL scores significantly improved after 24 weeks of linagliptin treatment, but not after metformin treatment. CONCLUSION: We did not find significantly better treatment-related QOL with linagliptin among Japanese patients with T2DM. In terms of treatment convenience, our data showed that linagliptin was superior to metformin. FUNDING: This study was financially supported by Nippon Boehringer Ingelheim Co., Ltd. and Eli Lilly and Company. The journal’s article processing fees were covered by a research fund from Juntendo University. CLINICAL TRIAL REGISTRATION: UMIN000022953. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0539-5) contains supplementary material, which is available to authorized users. Springer Healthcare 2018-11-27 2019-02 /pmc/articles/PMC6349297/ /pubmed/30483953 http://dx.doi.org/10.1007/s13300-018-0539-5 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Mita, Tomoya Hiyoshi, Toru Yoshii, Hidenori Chimori, Hiroko Ikeda, Kazuo Shimizu, Miho Kojima, Yuichi Yamamto, Hareaki Yasuda, Daijiro Sato, Junko Watada, Hirotaka The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus |
title | The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus |
title_full | The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus |
title_fullStr | The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus |
title_full_unstemmed | The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus |
title_short | The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus |
title_sort | effect of linagliptin versus metformin treatment-related quality of life in patients with type 2 diabetes mellitus |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349297/ https://www.ncbi.nlm.nih.gov/pubmed/30483953 http://dx.doi.org/10.1007/s13300-018-0539-5 |
work_keys_str_mv | AT mitatomoya theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT hiyoshitoru theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT yoshiihidenori theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT chimorihiroko theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT ikedakazuo theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT shimizumiho theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT kojimayuichi theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT yamamtohareaki theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT yasudadaijiro theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT satojunko theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT watadahirotaka theeffectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT mitatomoya effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT hiyoshitoru effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT yoshiihidenori effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT chimorihiroko effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT ikedakazuo effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT shimizumiho effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT kojimayuichi effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT yamamtohareaki effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT yasudadaijiro effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT satojunko effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus AT watadahirotaka effectoflinagliptinversusmetformintreatmentrelatedqualityoflifeinpatientswithtype2diabetesmellitus |